MX2021002264A - Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. - Google Patents

Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.

Info

Publication number
MX2021002264A
MX2021002264A MX2021002264A MX2021002264A MX2021002264A MX 2021002264 A MX2021002264 A MX 2021002264A MX 2021002264 A MX2021002264 A MX 2021002264A MX 2021002264 A MX2021002264 A MX 2021002264A MX 2021002264 A MX2021002264 A MX 2021002264A
Authority
MX
Mexico
Prior art keywords
methyl
ylethynyl
pyridazin
imidazo
trifluoromethyl
Prior art date
Application number
MX2021002264A
Other languages
English (en)
Inventor
Christopher K Murray
Leonard W Rozamus
John J Chaber
Pradeep Sharma
Original Assignee
Ariad Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50929140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021002264(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ariad Pharma Inc filed Critical Ariad Pharma Inc
Publication of MX2021002264A publication Critical patent/MX2021002264A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente describe formas cristalinas novedosas de la base libre de 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-N-{4-[(4-m etilpiperazin-1-il)metil]-3-(trifluorometil)fenil}benzamida y monoclorhidrato de 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil- N-{4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil}benza mida, sus composiciones farmacéuticas y métodos para su preparación y uso.
MX2021002264A 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. MX2021002264A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261736543P 2012-12-12 2012-12-12
US201261737007P 2012-12-13 2012-12-13
US201361788208P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
MX2021002264A true MX2021002264A (es) 2021-05-27

Family

ID=50929140

Family Applications (10)

Application Number Title Priority Date Filing Date
MX2015007578A MX359147B (es) 2012-12-12 2013-12-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3-iletinil)-4-me til-n-(4-[ (4-metilpiperazin-1-il) metil]-3-(trifluorometil) fenil) benzamida y su sal de monoclorhidrato.
MX2021002264A MX2021002264A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002258A MX2021002258A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002257A MX2021002257A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002254A MX2021002254A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002256A MX2021002256A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002259A MX2021002259A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002253A MX2021002253A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002255A MX2021002255A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002261A MX2021002261A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015007578A MX359147B (es) 2012-12-12 2013-12-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3-iletinil)-4-me til-n-(4-[ (4-metilpiperazin-1-il) metil]-3-(trifluorometil) fenil) benzamida y su sal de monoclorhidrato.

Family Applications After (8)

Application Number Title Priority Date Filing Date
MX2021002258A MX2021002258A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002257A MX2021002257A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002254A MX2021002254A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002256A MX2021002256A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002259A MX2021002259A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002253A MX2021002253A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002255A MX2021002255A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MX2021002261A MX2021002261A (es) 2012-12-12 2015-06-12 Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.

Country Status (9)

Country Link
US (9) US9493470B2 (es)
JP (4) JP6447508B2 (es)
CN (2) CN105188701A (es)
CA (3) CA3022250A1 (es)
CL (1) CL2015001643A1 (es)
HK (1) HK1218878A1 (es)
MX (10) MX359147B (es)
NZ (1) NZ709648A (es)
WO (2) WO2014093579A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3417912B1 (en) 2005-12-23 2020-08-12 ARIAD Pharmaceuticals, Inc. Bicyclic heteroaryl compounds
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
CA3022250A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
US9725454B2 (en) 2013-07-04 2017-08-08 Sandoz Ag Crystalline forms of ponatinib hydrochloride
CN104496940B (zh) * 2014-01-06 2017-03-15 广东东阳光药业有限公司 一种制备bcr‑abl抑制剂中间体的方法
EP3555066A1 (en) * 2016-12-15 2019-10-23 ARIAD Pharmaceuticals, Inc. Benzimidazole compounds as c-kit inhibitors
US10221184B2 (en) 2017-01-20 2019-03-05 Apicore Us Llc Polymorphs of ponatinib hydrochloride
US11072620B2 (en) 2017-06-20 2021-07-27 Apotex Inc. Crystalline forms of Ponatinib hydrochloride
CN118206614A (zh) * 2018-04-02 2024-06-18 隐形生物治疗公司 用于合成elamipretide的结晶二肽
EP3781568A1 (en) * 2018-06-22 2021-02-24 Johnson Matthey Public Limited Company Form of ponatinib
SG11202104438VA (en) 2018-11-01 2021-05-28 Syros Pharmaceuticals Inc Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2020223235A1 (en) 2019-04-29 2020-11-05 Incyte Corporation Mini-tablet dosage forms of ponatinib
CN111004240B (zh) * 2019-12-13 2020-12-01 山东铂源药业有限公司 一种泊那替尼中间体3-乙炔基咪唑并[1,2-b]哒嗪的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099067A (en) * 1988-08-05 1992-03-24 Northwestern University Use of ammonium formate as a hydrogen transfer reagent for reduction of chiral nitro compounds with retention of configuration
AU1465301A (en) 1999-11-08 2001-06-06 Schering Corporation Process for preparing n-(4-hydroxy-phenyl)-n'-(4'-aminophenyl)-piperazine
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
DE10021246A1 (de) 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
TW200418466A (en) 2002-11-06 2004-10-01 Smithkline Beecham Corp Chemical compounds
GB0230089D0 (en) 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
TW200529849A (en) 2003-11-28 2005-09-16 Novartis Ag Diaryl urea derivatives in the treatment of protein kinase dependent diseases
AU2004296242A1 (en) 2003-12-05 2005-06-23 Biovitrum Ab Improved synthesis of 2-substituted adenosines
US20080027076A1 (en) 2003-12-24 2008-01-31 Astrazeneca Ab Pyrimidines With Tie2 (Tek) Activity
ES2317079T3 (es) 2003-12-24 2009-04-16 Astrazeneca Ab Pirimidinas con actividad tie2 (tek).
BRPI0508790A (pt) 2004-04-07 2007-09-04 Applied Research Systems ácido carboxìlicos, uso de um ácido carboxìlico, composto farmacêutico, método de preparação de ácido carboxìlico e composto intermediário
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
WO2006103449A2 (en) 2005-03-31 2006-10-05 Astrazeneca Ab Saminopyrimidine derivates with tie2 inhibiting activity
US20100216798A1 (en) 2005-07-29 2010-08-26 Astellas Pharma Inc Fused heterocycles as lck inhibitors
EP1940843A4 (en) 2005-08-11 2010-09-15 Ariad Pharma Inc UNSATURATED HETEROCYCLIC DERIVATIVES
EP3417912B1 (en) 2005-12-23 2020-08-12 ARIAD Pharmaceuticals, Inc. Bicyclic heteroaryl compounds
CN101389338B (zh) * 2005-12-23 2013-06-26 阿里亚德医药股份有限公司 双环杂芳基化合物
AU2007249926B8 (en) 2006-05-08 2013-11-07 Ariad Pharmaceuticals, Inc. Monocyclic heteroaryl compounds
BRPI0710328A2 (pt) 2006-05-08 2011-08-09 Ariad Pharma Inc composto da fórmula i, um tautomer da mesma, ou um sal farmaceuticamente aceitável, hidrato ou outro solvato do mesmo e método para o tratamento de cáncer em um mamìfero necessitado do mesmo e composição
EP2107054A1 (en) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Antiproliferative compounds and therapeutic uses thereof
WO2010124047A1 (en) 2009-04-23 2010-10-28 Wyeth Llc Bisaryl alkynylamides as negative allosteric modulators of metabotropic glutamate receptor 5 (mglur5)
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
EA201290255A1 (ru) * 2009-10-30 2013-04-30 Ариад Фармасьютикалз, Инк. Способы и композиции для лечения рака
BR112013024171A2 (pt) * 2011-04-07 2016-12-13 Ariad Pharma Inc método para o tratamento e prevenção de uma condição neurodegenerativa
CN103596568A (zh) 2011-04-07 2014-02-19 阿里亚德医药股份有限公司 治疗帕金森病的方法以及组合物
US20150105377A1 (en) 2012-04-25 2015-04-16 Ariad Pharmaceuticals, Inc. Methods and Compositions for RAF Kinase Mediated Diseases
CA3022250A1 (en) * 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride

Also Published As

Publication number Publication date
MX2021002254A (es) 2021-05-27
WO2014093583A3 (en) 2014-08-07
MX359147B (es) 2018-09-17
US11192895B2 (en) 2021-12-07
US20190169196A1 (en) 2019-06-06
MX2021002258A (es) 2021-05-27
US10662197B2 (en) 2020-05-26
MX2021002257A (es) 2021-05-27
JP2018168191A (ja) 2018-11-01
JP6447508B2 (ja) 2019-01-09
US10125136B2 (en) 2018-11-13
JP2016503010A (ja) 2016-02-01
NZ709648A (en) 2020-05-29
US20150315194A1 (en) 2015-11-05
MX2021002253A (es) 2021-05-27
US11384086B2 (en) 2022-07-12
US20210277010A1 (en) 2021-09-09
US11192897B2 (en) 2021-12-07
CL2015001643A1 (es) 2015-10-02
US20210277012A1 (en) 2021-09-09
MX2021002261A (es) 2021-05-27
US20240083902A1 (en) 2024-03-14
US20210340149A1 (en) 2021-11-04
US9493470B2 (en) 2016-11-15
CA2815506A1 (en) 2014-06-12
WO2014093583A2 (en) 2014-06-19
CN105188701A (zh) 2015-12-23
HK1218878A1 (zh) 2017-03-17
US11279705B2 (en) 2022-03-22
US20170190707A1 (en) 2017-07-06
CN115043843A (zh) 2022-09-13
MX2021002259A (es) 2021-05-27
CA3022250A1 (en) 2014-06-12
WO2014093579A3 (en) 2014-07-10
MX2015007578A (es) 2016-03-21
JP7042175B2 (ja) 2022-03-25
US20210024527A1 (en) 2021-01-28
JP7352841B2 (ja) 2023-09-29
CA3167093A1 (en) 2014-06-12
WO2014093579A2 (en) 2014-06-19
US11192896B2 (en) 2021-12-07
US20210277011A1 (en) 2021-09-09
CA2815506C (en) 2018-12-11
MX2021002255A (es) 2021-05-27
JP2023179498A (ja) 2023-12-19
MX2021002256A (es) 2021-05-27
JP2022037122A (ja) 2022-03-08

Similar Documents

Publication Publication Date Title
MX2021002261A (es) Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
PH12017500166A1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
PH12015502792A1 (en) Crystalline bromodomain inhibitors
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
IL232462A (en) Annals of 2- (1, 2, 3-triazole-2-ram) benzamide and 3- (3,2,1-triazole-2-ram) picolinamide, containing and using pharmaceutical preparations
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
HK1214822A1 (zh) 新型 苄氧基 苯基 己- -炔酸衍生物、其製備方法、和包括其作為有效成分的用於預防和治療代謝性疾病的藥物組合物
PH12018501236A1 (en) Pharmaceutical composition comprising a potent inhibitor urat1
IN2014DN09347A (es)
PH12018501331A1 (en) Crystalline forms of thienopyrimidine compound
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
PH12017501832A1 (en) Stabilized pharmaceutical composition
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
MX2014002141A (es) Carboxamidas de n-(5-cicloalquil - o 5-heterociclil-)-piridin-3-il o.
IN2013CH01248A (es)